New early data reveals that 36% of people starting the new Wegovy pill had never used a GLP-1 before, suggesting oral options may be expanding access rather than simply replacing injections.

They also examine why Eli Lilly is building $1.5 billion in inventory ahead of its anticipated oral GLP-1 launch, and what that could signal about the company's plans to avoid the shortages seen during the rollout of Mounjaro and Zepbound.

Meanwhile, the FDA has issued a warning to Novo Nordisk over a television advertisement for oral Wegovy, calling parts of the messaging false or misleading.

In other stories, AstraZeneca moves its oral GLP-1 candidate into Phase 3, fast food companies including McDonald's begin adapting menus for GLP-1 users, and a new lawsuit raises questions about the marketing of oral tirzepatide.

The episode also explores a growing media narrative around nutrient intake and reduced appetite, and reviews new research from the Clayman Thyroid Center pushing back on fears that GLP-1 medications increase the risk of common thyroid cancers.

Christopher and Laraine share the news, context, and patient relevance to help viewers stay informed as obesity treatment continues to evolve.